Evidence map›Paper›PMID 36011265›Full record

ArticleGenes2022

A Rare

Maria Kabbage, Jihenne Ben Aissa-Haj, Houcemeddine Othman, Amira Jaballah-Gabteni, Sarra Laarayedh, Sahar Elouej, Mouna Medhioub, Haifa Tounsi Kettiti, Amal Khsiba, Moufida Mahmoudi and 8 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Maria KabbageDepartment of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia.
Jihenne Ben Aissa-HajDepartment of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia.ORCID 0000-0002-1368-7169
Houcemeddine OthmanSydney Brenner Institute for Molecular Bioscience, University of the Witwatersrand, Johannesburg 2000, South Africa.ORCID 0000-0002-1159-6482
Amira Jaballah-GabteniDepartment of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia.
Sarra LaarayedhDepartment of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia.
Sahar ElouejMarseille Medical Genetics, Aix Marseille University, INSERM, 13007 Marseille, France.
Mouna MedhioubLaboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, Tunis EL Manar University, Tunis 1002, Tunisia.
Haifa Tounsi KettitiDepartment of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia.
Amal KhsibaLaboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, Tunis EL Manar University, Tunis 1002, Tunisia.
Moufida MahmoudiLaboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, Tunis EL Manar University, Tunis 1002, Tunisia.
Houda BelFekihLaboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, Tunis EL Manar University, Tunis 1002, Tunisia.
Afifa MaaloulDepartment of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia.
Hassen TouinsiDepartment of Surgery, Mohamed Tahar Maamouri Hospital, Nabeul 8000, Tunisia.
Lamine HamzaouiLaboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, Tunis EL Manar University, Tunis 1002, Tunisia.
Emna ChelbiLaboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, Tunis EL Manar University, Tunis 1002, Tunisia.
Sonia AbdelhakLaboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, Tunis EL Manar University, Tunis 1002, Tunisia.ORCID 0000-0001-8466-5525
Mohamed Samir BoubakerDepartment of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia.
Mohamed Mousaddak AzzouzLaboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, Tunis EL Manar University, Tunis 1002, Tunisia.
Institut Pasteur de Tunis · TNHôpital Sahloul · TNInserm · FRUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several syndromic forms of digestive cancers are known to predispose to early-onset gastric tumors such as Hereditary Diffuse Gastric Cancer (HDGC) and Lynch Syndrome (LS). LSII is an extracolonic cancer syndrome characterized by a tumor spectrum including gastric cancer (GC). In the current work, our main aim was to identify the mutational spectrum underlying the genetic predisposition to diffuse gastric tumors occurring in a Tunisian family suspected of both HDGC and LS II syndromes. We selected the index case “JI-021”, which was a woman diagnosed with a Diffuse Gastric Carcinoma and fulfilling the international guidelines for both HDGC and LSII syndromes. For DNA repair, a custom panel targeting 87 candidate genes recovering the four DNA repair pathways was used. Structural bioinformatics analysis was conducted to predict the effect of the revealed variants on the functional properties of the proteins. DNA repair genes panel screening identified two variants: a rare MSH2 c.728G>A classified as a variant with uncertain significance (VUS) and a novel FANCD2 variant c.1879G>T. The structural prediction model of the MSH2 variant and electrostatic potential calculation showed for the first time that MSH2 c.728G>A is likely pathogenic and is involved in the MSH2-MLH1 complex stability. It appears to affect the MSH2-MLH1 complex as well as DNA-complex stability. The c.1879G>T FANCD2 variant was predicted to destabilize the protein structure. Our results showed that the MSH2 p.R243Q variant is likely pathogenic and is involved in the MSH2-MLH1 complex stability, and molecular modeling analysis highlights a putative impact on the binding with MLH1 by disrupting the electrostatic potential, suggesting the revision of its status from VUS to likely pathogenic. This variant seems to be a shared variant in the Mediterranean region. These findings emphasize the importance of testing DNA repair genes for patients diagnosed with diffuse GC with suspicion of LSII and colorectal cancer allowing better clinical surveillance for more personalized medicine.

Indexed as

CarcinomaLynch Syndrome IIStomach NeoplasmsDNA Mismatch RepairFemaleGerm-Line MutationHumansMutS Homolog 2 ProteinTunisiaMSH2 protein, humanMutS Homolog 2 ProteinCDH1-negative caseDNA repair genesgenetic screeningHDGClynch syndrome IIMSH2target gene sequencing

Identifiers

PMID36011265
PMCPMC9407052
OpenAlexW4288440903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.